ATE480569T1 - Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen - Google Patents

Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen

Info

Publication number
ATE480569T1
ATE480569T1 AT07766524T AT07766524T ATE480569T1 AT E480569 T1 ATE480569 T1 AT E480569T1 AT 07766524 T AT07766524 T AT 07766524T AT 07766524 T AT07766524 T AT 07766524T AT E480569 T1 ATE480569 T1 AT E480569T1
Authority
AT
Austria
Prior art keywords
independently
polypeptide
integer
amino acid
activated ras
Prior art date
Application number
AT07766524T
Other languages
English (en)
Inventor
Coupade Catherine De
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis filed Critical Cellectis
Application granted granted Critical
Publication of ATE480569T1 publication Critical patent/ATE480569T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07766524T 2006-06-12 2007-06-08 Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen ATE480569T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290952A EP1867661A1 (de) 2006-06-12 2006-06-12 Zusammensetzungen und Verfahren zur Einschleusung von Anti-aktivierten-Ras-Antikörpern in Zellen
PCT/IB2007/001546 WO2007144730A1 (en) 2006-06-12 2007-06-08 Compositions and methods for delivering anti-activated ras antibodies into cells

Publications (1)

Publication Number Publication Date
ATE480569T1 true ATE480569T1 (de) 2010-09-15

Family

ID=37102144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07766524T ATE480569T1 (de) 2006-06-12 2007-06-08 Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen

Country Status (7)

Country Link
US (1) US20120141478A1 (de)
EP (2) EP1867661A1 (de)
AT (1) ATE480569T1 (de)
DE (1) DE602007009116D1 (de)
DK (1) DK2044125T3 (de)
ES (1) ES2352321T3 (de)
WO (1) WO2007144730A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
US9328142B2 (en) 2011-05-25 2016-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of RAS oncoproteins
GB201322396D0 (en) * 2013-12-18 2014-02-05 Univ Nottingham Transduction
JP7091373B2 (ja) 2017-06-22 2022-06-27 カタリスト・バイオサイエンシーズ・インコーポレイテッド 改変された膜型セリンプロテアーゼ１（ｍｔｓｐ－１）ポリペプチドおよび使用方法
AU2018301651B2 (en) 2017-07-10 2023-05-18 Sri International A peptide saporin conjugate for the treatment of cancer
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
EP3810182A4 (de) 2018-06-19 2022-08-24 BioNTech US Inc. Neoantigene und ihre verwendungen
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
PE20211664A1 (es) 2018-12-28 2021-08-26 Catalyst Biosciences Inc Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US8003595B2 (en) * 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
CA2506128A1 (en) * 2002-11-15 2004-06-03 Medical Research Council Anti-activated ras antibodies
BRPI0413521A (pt) * 2003-08-14 2006-10-10 Diatos seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares

Also Published As

Publication number Publication date
EP2044125A1 (de) 2009-04-08
EP2044125B1 (de) 2010-09-08
US20120141478A1 (en) 2012-06-07
WO2007144730A1 (en) 2007-12-21
DK2044125T3 (da) 2011-01-10
EP1867661A1 (de) 2007-12-19
DE602007009116D1 (de) 2010-10-21
ES2352321T3 (es) 2011-02-17

Similar Documents

Publication Publication Date Title
ATE480569T1 (de) Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
AR068566A1 (es) Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
CY1118845T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα α il-17
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
WO2008031133A3 (en) Borrelia antigens
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
EP2532366A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von krebs
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
MX349513B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
EP2532365A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
ME02602B (de) Gerinnungshemmende gegenmittel
Hamilton et al. Improved bone morphogenetic protein-2 retention in an injectable collagen matrix using bifunctional peptides
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
ATE514718T1 (de) Peptabody für krebsbehandlung
EA202091496A1 (ru) Вариант инсектицидного гена axmi115 и способы его применения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2044125

Country of ref document: EP